• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 17, 2019

View Archived Issues

Abstract painter: ASCO's KRAS rollouts red Haring? Early brushwork pleases

With abstracts presaging the customary avalanche of data due from the American Society of Clinical Oncology (ASCO) meeting next month, the mechanism of KRAS inhibition caused an expectedly large share of talk, though efforts remain far from mature, and too fresh for big conclusions. Read More

Tafasitamab delivers for Morphosys in DLBCL; rolling BLA by year-end

DUBLIN – Morphosys AG took a significant step toward realizing its ambition to begin marketing its first product by mid-next year, as its CD19-directed antibody, tafasitamab (MOR-208), hit the primary endpoint of a pivotal phase II trial in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

Read More

Truvada pricing hearing laden with passionate politics, some insight

Passion, politics and prices were all on display Thursday as the House Oversight and Reform Committee attempted to delve into the pricing of Gilead Sciences Inc.'s Truvada, which is used to both treat and prevent HIV. Read More

Evolving strategies for navigating the blood-brain barrier

Following the successful progress of gene therapies in treating rare disease, they are now beginning to be applied to CNS disorders, including Parkinson's and Alzheimer's disease, and other serious conditions. Drug delivery to the brain has long been a challenge, and a great deal of research is being focused on identifying various strategies that are able to ferry medicines across the blood-brain barrier (BBB), which typically blocks the transport of molecules and particles into the brain, and effectively deliver their therapeutic payloads. In this two-part feature, the progress being made in the field will be explored. Read More

Nanoparticles lead to big deal between Parvus, Genentech to treat autoimmune diseases

Parvus Therapeutics Inc. and Genentech Inc. have agreed to develop, manufacture and commercialize Parvus' therapeutics to treat inflammatory bowel, autoimmune liver and celiac diseases. The platform gets the job done without immunosuppression, a singular approach and technology. Read More

Huons collaboration offers global network for biobetter, rare disease drug pipeline

HONG KONG - Pharmaceutical manufacturer Huons Co. Ltd. and biopharmaceutical research and development venture Genexine Inc. inked a memorandum of understanding for a deal, under which they will combine Genexine's biobetters and rare disease pipeline with Huons' existing global commercial network. Read More

'Greatest emerging market'? Cannabis-based drug R&D finally going mainstream

TEL AVIV, Israel – An awakening is underway in the biotech field to develop new products from cannabis, with efforts based on strong science and supported by clinical trials and rigorous research, particularly into the many potential uses of cannabinoids. Read More

Korea to collaborate with Italy and Japan on cancer biomarker

HONG KONG – The Korea Cancer Biomarker Consortium (KCBC), a research group of 13 university hospitals in South Korea, and South Korean biotech Cbsbioscience Inc. inked a deal with medical research institutes in Italy and Japan to develop biomarkers aimed at improving the efficiency of cancer drugs. Read More

Other news to note

Dogma Therapeutics LLC, of Cambridge, Mass., disclosed an oral PCSK9 inhibitor program. In dyslipidemic nonhuman primates, multiple Dogma inhibitors produced significant and robust lowering of LDL cholesterol following multiple weeks of administration. Read More

Financings

Hemostemix Inc., of Calgary, Alberta, said it has concluded a first closing of the $1 million nonbrokered private placement of convertible debentures, and issued debentures in the amount of $525,000. The net proceeds will be used to continue to fund the company's phase II trial for critical limb ischemia and for general working capital. Read More

Clinical data for May 16, 2019

Read More

Regulatory actions for May 16, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 20, 2025.
  • Brain, syringe hovering over hands

    NICE rejects Lilly‘s Kisunla and Eisai‘s Leqembi

    BioWorld
    To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe